Deutsche Bank AG Raises Stock Holdings in Celldex Therapeutics, Inc. $CLDX

Deutsche Bank AG boosted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 13.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 138,289 shares of the biopharmaceutical company’s stock after acquiring an additional 16,788 shares during the quarter. Deutsche Bank AG owned 0.21% of Celldex Therapeutics worth $2,510,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. GAMMA Investing LLC grew its holdings in shares of Celldex Therapeutics by 6,665.9% in the first quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 2,933 shares during the last quarter. Aquatic Capital Management LLC purchased a new stake in Celldex Therapeutics in the 4th quarter valued at about $121,000. Hsbc Holdings PLC bought a new position in Celldex Therapeutics in the 4th quarter worth about $233,000. Ameriprise Financial Inc. bought a new position in Celldex Therapeutics in the 4th quarter worth about $251,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Celldex Therapeutics during the first quarter worth approximately $269,000.

Celldex Therapeutics Stock Performance

CLDX stock opened at $24.02 on Wednesday. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $47.00. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -7.98 and a beta of 1.22. The firm has a 50-day simple moving average of $22.06 and a two-hundred day simple moving average of $20.68.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.01. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. The firm had revenue of $0.73 million for the quarter, compared to the consensus estimate of $1.13 million. As a group, equities analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CLDX. UBS Group lowered their price target on Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a report on Friday, May 9th. Morgan Stanley lowered their target price on Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, May 9th. The Goldman Sachs Group cut their price target on Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating on the stock in a research note on Friday, May 9th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Celldex Therapeutics in a report on Friday, June 13th. Finally, Canaccord Genuity Group assumed coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They issued a “buy” rating and a $64.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $51.75.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.